Clinical Trials Browser

Nasopharyngeal Carcinoma × Nivolumab × Clear all

NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Phase 2 Active not recruiting

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT06029270 2026-06-03

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT06064097 2026-06-03

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT05904080 2026-05-18

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT03267498 2026-01-12

Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

Phase 2 Completed

40 enrolled 14 charts

Nasopharyngeal Carcinoma

NCT04458909 2025-10-03

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Phase 3 Terminated

15 enrolled 17 charts

Nasopharyngeal Carcinoma

NCT06019130 2024-05-16

NPC-Nivo

Phase 2 Recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT03097939 2023-10-11

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT03390738 2021-05-03

Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy

Phase 2 Withdrawn

Nasopharyngeal Carcinoma

NCT02339558 2019-09-13

Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer

Phase 2 Completed

45 enrolled 12 charts

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms